Morgan Stanley resumed coverage on Baxter with a new price target
$BAX
Medical/Dental Instruments
Health Care
Morgan Stanley resumed coverage of Baxter with a rating of Equal-Weight and set a new price target of $45.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/31/2025 | Buy → Hold | Argus | |
| 8/4/2025 | $25.00 | Buy → Hold | Stifel |
| 8/1/2025 | $25.00 | Buy → Neutral | Goldman |
| 2/26/2025 | $42.00 | Buy | Goldman |
| 2/24/2025 | Hold → Buy | Argus | |
| 2/20/2025 | $39.00 | Overweight | Barclays |
| 7/15/2024 | $39.00 → $30.00 | Equal-Weight → Underweight | Morgan Stanley |
| 5/30/2024 | $36.00 | Neutral | Goldman |
For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c
4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)
4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)
4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)
10-Q - BAXTER INTERNATIONAL INC (0000010456) (Filer)
8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)
8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)
Funding from the Baxter Foundation builds on 15+ year partnership with Northwestern University's School of Education and Social Policy to promote engagement and confidence in Science, Technology, Engineering and Mathematics (STEM) for Chicagoland youth and professional development opportunities for Chicagoland teachers Three-year funding will support continuation and evolution of existing Baxter Center for Science Education programs New grant announcement coincides with National STEM Day to drive greater awareness of the need to collectively support the next generation of innovators The Baxter Foundation, the philanthropic arm of Baxter International Inc. (NYSE:BAX), a global medtech
Third-quarter sales from continuing operations of $2.84 billion increased 5% on a reported basis and 2% on an operational basis1,2 Third-quarter U.S. GAAP3 diluted earnings per share (EPS) (loss) from continuing operations of ($0.10); adjusted diluted EPS from continuing operations of $0.69 Andrew Hider joined the company as president and chief executive officer (CEO), now leading the company's focus to drive continuous improvement and sustainable growth and create shareholder value Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the third quarter of 2025. "I joined Baxter because it's a global healthcare leader – an iconic brand with an
Baxter International Inc. (NYSE:BAX), a leading global medtech company, will host a conference call to discuss its third-quarter 2025 financial results on Thursday, October 30, 2025 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I156235 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.com. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. About Baxter At Baxter, we are everywhere healthcare happens – and everywh
Argus downgraded Baxter from Buy to Hold
Stifel downgraded Baxter from Buy to Hold and set a new price target of $25.00
Goldman downgraded Baxter from Buy to Neutral and set a new price target of $25.00
Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the appointment of Andrew Hider as president and chief executive officer (CEO), and a member of its board of directors. Mr. Hider will assume his responsibilities at Baxter no later than Sept. 3, 2025, or an earlier date pending completion of his current employment commitments. Brent Shafer, who has served as chair and interim CEO since February 2025, will then transition to independent chair of the Baxter Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250706840140/en/Andrew Hider Appointed Baxter's Next CEO Since 2017, Mr. Hider has served as
Amerant Bancorp Inc. (NYSE:AMTB) ("Amerant" or "the Company") and its subsidiary, Amerant Bank, N.A. (the "Bank"), today announced the appointment of two accomplished executives, Patricia "Patty" Morrison and Jack Kopnisky, to the Board of Directors of the Company and the Bank. Their addition reflects the Company's continued commitment to strategic growth and further strengthening of the Board of Directors and executive management. "We are delighted to welcome both Patty and Jack to our Board of Directors," said Jerry Plush, Chairman and CEO of Amerant and the Bank. "Patty's deep technology leadership and extensive board expertise, paired with Jack's enviable experience in leading high pe
Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca
SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)
SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)
SC 13G - BAXTER INTERNATIONAL INC (0000010456) (Subject)
Third-quarter sales from continuing operations of $2.84 billion increased 5% on a reported basis and 2% on an operational basis1,2 Third-quarter U.S. GAAP3 diluted earnings per share (EPS) (loss) from continuing operations of ($0.10); adjusted diluted EPS from continuing operations of $0.69 Andrew Hider joined the company as president and chief executive officer (CEO), now leading the company's focus to drive continuous improvement and sustainable growth and create shareholder value Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the third quarter of 2025. "I joined Baxter because it's a global healthcare leader – an iconic brand with an
Baxter International Inc. (NYSE:BAX), a leading global medtech company, will host a conference call to discuss its third-quarter 2025 financial results on Thursday, October 30, 2025 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I156235 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.com. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. About Baxter At Baxter, we are everywhere healthcare happens – and everywh
Second-quarter sales from continuing operations of $2.81 billion increased 4% on a reported basis and 1% on an operational basis, in line with the company's previously issued guidance1,2 Second-quarter U.S. GAAP3 diluted earnings per share (EPS) from continuing operations of $0.24; adjusted diluted EPS from continuing operations of $0.59, in line with the company's previously issued guidance Recently announced appointment of Andrew Hider as president and chief executive officer (CEO)4 supports company's focus to accelerate innovation, drive sustainable growth, enhance operational effectiveness and create shareholder value Baxter International Inc. (NYSE:BAX), a global medtech lead